Even though cooler days may seem far off, now is the best time to plan ahead for a healthy winter. One common respiratory ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

Most people experience mild RSV reinfections throughout their lifetime, particularly during respiratory virus season (November to March in Canada). People are at higher risk if they are older than 75 ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Clinicians and healthcare professionals should target adults aged 70 and over with underlying health conditions instead of the general population, when it comes to efforts to reduce spending and ...

The respiratory syncytial virus (RSV) can be particularly dangerous for older people with chronic medical conditions. Each ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Administering the respiratory syncytial virus (RSV) in older adults with underlying health conditions may be a cost-effective ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...